Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Price Target at $4.23

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been assigned a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.2273.

GDRX has been the topic of several analyst reports. Leerink Partners set a $5.00 target price on GoodRx in a research report on Thursday, August 6th. TD Cowen increased their price target on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Wells Fargo & Company raised their price target on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Citigroup lifted their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, UBS Group upped their price objective on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a report on Thursday, August 13th.

GoodRx Stock Up 5.0%

GDRX stock opened at $3.56 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The firm’s 50-day simple moving average is $3.34 and its 200 day simple moving average is $2.77. The stock has a market cap of $1.22 billion, a PE ratio of 89.02, a price-to-earnings-growth ratio of 1.69 and a beta of 1.59.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. During the same period in the previous year, the business posted $0.09 EPS. GoodRx’s revenue was down 1.3% on a year-over-year basis. As a group, sell-side analysts predict that GoodRx will post 0.16 EPS for the current year.

Insider Activity at GoodRx

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 2,760,995 shares of company stock worth $9,673,207. 5.87% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GoodRx

Institutional investors have recently added to or reduced their stakes in the company. LSV Asset Management lifted its holdings in GoodRx by 20.0% in the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock valued at $7,658,000 after acquiring an additional 471,319 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of GoodRx by 1.5% in the 1st quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company’s stock worth $6,389,000 after purchasing an additional 48,800 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of GoodRx by 192.6% in the 2nd quarter. California State Teachers Retirement System now owns 1,684,431 shares of the company’s stock worth $4,851,000 after purchasing an additional 1,108,766 shares in the last quarter. Prescott Group Capital Management L.L.C. bought a new stake in shares of GoodRx in the 4th quarter worth approximately $4,812,000. Finally, Technology Crossover Management X Ltd. acquired a new stake in GoodRx during the second quarter valued at approximately $4,762,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a consumer-focused healthcare technology platform in the United States. Its website and mobile application help consumers compare prescription drug prices at participating pharmacies and access coupons and other savings tools. GoodRx also provides information about medications, health conditions and treatment options.

The company offers GoodRx Gold, a subscription-based program that provides additional prescription savings, as well as telehealth services that connect consumers with licensed healthcare professionals for certain medical consultations and prescriptions.